Investor Presentation
Prevest Denpro H1 FY27 Investor Presentation
Prevest Denpro submitted its investor presentation for H1 FY27, reporting consolidated revenue growth of 18.3% and PAT growth of 20.9% year over year.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.



Healthcare Equipment & Supplies
Medical Equipment & Supplies
459 Cr
Low Risk
20.3
60.5
1.9
3.4
514.00
318.15
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Prevest Denpro submitted its investor presentation for H1 FY27, reporting consolidated revenue growth of 18.3% and PAT growth of 20.9% year over year.
Dividend
Prevest Denpro fixed November 20, 2026 as the record date for its interim dividend for the half year ended September 30, 2026.
Financial Results
Prevest Denpro approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, along with a 10% interim dividend.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
6
Bullish
5
Bearish
31
Neutral
6
Bullish
9
Bearish
28
Neutral
0
Bullish
4
Prevest Denpro Ltd (PREVEST) is currently trading at 389.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Prevest Denpro Limited manufactures and markets more than 100 dental consumables spanning restorative materials, endodontics, preventive care, orthodontics, impression materials, laboratory products, disinfectants, and digital dentistry solutions. Its integrated Jammu manufacturing and R&D platform serves clinicians, laboratories, distributors, and increasingly direct consumers across domestic and international markets. International markets are central to the business rather than incidental: exports represented 59% of H1 FY27 revenue, with more than 90 destinations and direct presence through subsidiaries in the United States and UAE. Export revenue grew 14.90% year over year in H1 FY27, demonstrating continued global traction and geographic diversification. H1 FY27 consolidated revenue grew 18.3%, while PAT increased 20.9%, supported by a 39.0% EBITDA margin and 27.6% PAT margin. The combination of strong growth, high profitability, zero long-term debt, and a ₹1.00 interim dividend indicates substantial financial flexibility for expansion and shareholder returns. Digital dentistry is the company’s principal next growth frontier. Prevest Denpro Limited is developing in-house dental printer capabilities, specialized printing resins, and integrated restorative workflows, while investing ₹81.14 lakhs in R&D during H1 FY27 across 3D printing, bioceramics, composites, preventive products, and disinfectants. The company is attempting to localize critical raw materials while broadening manufacturing into hygiene, oral care, and biomaterials. This strategy could improve supply-chain resilience and enlarge the addressable market, but execution, regulatory approvals, market acceptance, and the eventual economics of these newer categories remain important validation points.
Over the past 52 weeks, Prevest Denpro Ltd has traded between a low of ₹318.15 and a high of ₹514.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Prevest Denpro Ltd has a market capitalization of approximately 459.11. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Prevest Denpro Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.34 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 459.11 Cr, Prevest Denpro Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Prevest Denpro Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Prevest Denpro Ltd is 20.34. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Prevest Denpro reported that exports represented 59% of H1 FY27 revenue. Domestic sales represented the remaining 41% for the half year ended 30 September 2026.
Prevest Denpro is developing in-house 3D-printer capabilities and a broader portfolio of specialized dental printing resins. Its FY27 roadmap also refers to digital workflows, integrated restorative solutions and a complete dental 3D-printing ecosystem.
Prevest Denpro reported consolidated PAT of Rs 12.03 crore in H1 FY 26-27. That was 20.9% higher than Rs 9.95 crore in H1 FY 25-26. PAT margin increased to 27.6% from 27.1%.
Prevest Denpro declared its Q4 FY26 results on May 27, 2026, for the quarter ended March 31, 2026.